Cleveland Clinic now offers an advanced genomic testing platform as standard of care to patients with cancer, according to a Nov. 18 press release.
With the new technology, researchers can now examine 22,000 genes in the human genome — the most extensive profiling available today. Previous testing was limited to the standard 600 or fewer known genes associated with cancer.
"This technology is a critical new tool for physicians to develop individualized treatment plans for patients based on their unique genomic profile," said Timothy Chan, MD, PhD, director of the Center for Immunotherapy and Precision Immuno-Oncology. "It’s also an opportunity for our patients to learn about their own disease while participating in precision oncology-driven clinical trials."
Clinical trials are currently underway at the system testing treatments that may impact the genetic alterations revealed by tumor genomic testing.